Annual Report 2020
Department of Hematology
Koji Izutsu, Dai Maruyama, Tatsuya Suzuki, Wataru Munakata, Suguru Fukuhara, Shinichi Makita, Hanae Ida, Rika Hosoba, Yoshikazu Hori
Introduction
The Department of Hematology of the National Cancer Center Hospital is dedicated to supporting patients with hematologic malignancies including leukemia, lymphoma, and myeloma by offering state-of-the art diagnosis and treatment options and developing novel treatment and diagnostic methods through clinical trials and translational research. Our Lymphoma Program has a history of pioneering clinical research on adult T-cell leukemia/lymphoma and other lymphoid malignancies, and has been leading the development of novel agents and cell therapies for lymphoid malignancies in Japan.
The Team and What We Do
We offer the most advanced diagnostic procedures and care for patients with hematologic malignancies (e.g., leukemia, lymphoma, myelodysplastic syndrome, and multiple myeloma), both on an outpatient and inpatient basis (Table 1). The medical treatments we offer include chemotherapy, immunotherapy, radioimmunotherapy, and chimeric antigen receptor (CAR) T-cell therapy. We treat patients in collaboration with experts from our center's Department of Hematopoietic Stem Cell Transplantation, Department of Radiation Oncology, and Department of Experimental Therapeutics. Moreover, experts at our center's Department of Pathology and Department of Clinical Laboratories offer state-of-the-art diagnosis to guide treatment.
Six staff physicians and clinical fellows at our department are in charge of specialized care for patients with hematologic malignancies.
Research activities
We have launched a tumor sample banking system for hematological malignancies for future research use. These samples include tumor DNA derived from bone marrow, peripheral blood, and other tumor tissue obtained through core needle biopsy. We are conducting clinical and clinical-pathology research for hematological malignancies, especially for malignant lymphoma. In 2018, in collaboration with other departments, we launched MASTER KEY HEM registration study for rare hematologic malignancies incorporating biomarkers. In 2019, we launched an investigator-initiated clinical trial of a PD-L1 antibody for extranodal NK/T-cell lymphoma. Our department is devoted to activities of the leading clinical study groups on hematological malignancies in Japan; namely, the Japan Clinical Oncology Group, Lymphoma Study Group (JCOG LSG) and the Japan Adult Leukemia Study Group (JALSG). This year, we authored or coauthored 19 articles related to hematological malignancies.
Clinical trials
In 2019, we conducted 61 corporate-sponsored clinical trials, including many global studies, one first-in-human study, and 10 new studies that started from April 2019 to March 2020. We also conducted several investigator-initiated clinical trials of JCOG and JALSG.
Education
We have been offering a training program for young hematologists and/or oncologists. Many of our graduates are actively engaged in hematology and oncology societies.
Future Prospects
The Department of Hematology will continue to address unmet needs in the treatment of hematological malignancies. We are focusing on developing treatments for rare hematologic malignancies including rare subtypes of lymphoma. Our future plans include genome-based medicine. Information obtained from genomic tests has become imperative in the diagnosis according to the current WHO classification of hematologic malignancies, prognosis prediction, and for guiding selection of molecular-targeted agents.
List of papers published in 2020
Journal
1. Izutsu K, Ando K, Ennishi D, Shibayama H, Suzumiya J, Yamamoto K, Ichikawa S, Kato K, Kumagai K, Patel P, Iizumi S, Hayashi N, Kawasumi H, Murayama K, Nagai H. Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study. Cancer Sci, 112:2405-2415, 2021
2. Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, Moriuchi Y, Tsujimura H, Kubota N, Yamamoto G, Igarashi T, Izutsu K, Yoshida S, Kojima K, Uchida T, Inoue Y, Tsukamoto N, Ohtsuka E, Suzuki S, Inaguma Y, Ichikawa S, Gomyo H, Ushijima Y, Nosaka K, Kurata M, Tanaka Y, Ueda R, Mizokami M, Kusumoto S. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. Cancer Sci, 112:1943-1954, 2021
3. Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, Özcan M, Hong X, Zhu J, Jin J, Belada D, Bergua JM, Piazza F, Mócikova H, Molinari AL, Yoon DH, Cavallo F, Tani M, Yamamoto K, Izutsu K, Kato K, Czuczman M, Hersey S, Kilcoyne A, Russo J, Hudak K, Zhang J, Wade S, Witzig TE, Vitolo U. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. J Clin Oncol, 39:1317-1328, 2021
4. Takagi S, Ogura S, Araoka H, Uchida N, Mitsuki T, Yuasa M, Kageyama K, Kaji D, Taya Y, Nishida A, Kimura M, Ishiwata K, Yamamoto H, Yamamoto G, Asano-Mori Y, Koike Y, Izutsu K, Wake A, Makino S, Yoneyama A, Taniguchi S. The impact of graft cell source on bloodstream infection in the first 100 days after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant, 2021
5. Polprasert C, Takeuchi Y, Makishima H, Wudhikarn K, Kakiuchi N, Tangnuntachai N, Assanasen T, Sitthi W, Muhamad H, Lawasut P, Kongkiatkamon S, Bunworasate U, Izutsu K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Yoshida K, Rojnuckarin P. Frequent mutations in HLA and related genes in extranodal NK/T cell lymphomas. Leuk Lymphoma, 62:95-103, 2021
6. Kashima J, Yoshida M, Jimbo K, Izutsu K, Ushiku T, Yonemori K, Yoshida A. ALK-positive Histiocytosis of the Breast: A Clinicopathologic Study Highlighting Spindle Cell Histology. Am J Surg Pathol, 45:347-355, 2021
7. Kageyama K, Uchida N, Yamamoto H, Takagi S, Ebihara M, Yuasa M, Kaji D, Nishida A, Ishiwata K, Yamamoto G, Asano-Mori Y, Izutsu K, Wake A, Yoneyama A, Makino S, Taniguchi S. HHV-6 associated diseases are one of the major factors on higher early CNS complications in CB recipients than in those of BM/PBSC. Bone Marrow Transplant, 56:686-688, 2021
8. Fujimoto A, Ishida F, Izutsu K, Yamasaki S, Chihara D, Suzumiya J, Mitsui T, Doki N, Sakai H, Kobayashi H, Kanda J, Fukuda T, Atsuta Y, Suzuki R. Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia. Bone Marrow Transplant, 56:347-356, 2021
9. Suzuki T, Fukuhara S, Nomoto J, Yamashita S, Maeshima AM, Ito Y, Hatta S, Yuda S, Makita S, Munakata W, Suzuki T, Maruyama D, Taniguchi H, Ushijima T, Izutsu K, Tobinai K, Kobayashi Y. Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors. Haematologica, 106:593-596, 2021
10. Maruyama D, Iida S, Ogawa G, Fukuhara N, Seo S, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Hangaishi A, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Minauchi K, Ohtsuka E, Hanamura I, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Tsukasaki K, Nagai H. Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105). Br J Haematol, 192:531-541, 2021
11. Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, Choi I, Humphrey K, Kim SY, Okubo S, Ogawa N, Nishimura Y, Salem AH, Maruyama D. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Int J Hematol, 113:370-380, 2021
12. Yamamoto N, Maeshima AM, Taniguchi H, Makita S, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Izutsu K. CD5-negative blastoid variant mantle cell lymphoma: a diagnostic dilemma. Hum Pathol, 111:84-91, 2021
13. Miyamoto K, Watanabe T, Wakabayashi M, Nakamura K, Watanabe Y, Maruyama D, Tobinai K, Tsukasaki K, Fukuda H. Comparison of the International Workshop Criteria and the Response Evaluation Criteria in Solid Tumors for indolent B-cell lymphoma. Int J Clin Oncol, 26:429-437, 2021
14. Izutsu K, Ogura M, Tobinai K, Hatake K, Sakamoto S, Nishimura M, Hoshino M. Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study. Int J Hematol, 113:404-412, 2021
15. Izutsu K, Ogura M, Tobinai K, Hatake K, Sakamoto S, Nishimura M, Hoshino M. Correction to: Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study. Int J Hematol, 113:611, 2021
16. Izutsu K, Kinoshita T, Takizawa J, Fukuhara S, Yamamoto G, Ohashi Y, Suzumiya J, Tobinai K. A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia. Jpn J Clin Oncol, 51:408-415, 2021
17. Kinoshita T, Watanabe T, Itoh K, Yoshimura K, Tobinai K, Ogura M, Yamaguchi M, Kurosawa M, Imaizumi Y, Ota S, Kaba H, Mukai K, Nakamura S, Ohshima K, Hotta T, Tsukasaki K, Nagai H, Shimoyama M. Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study - JCOG0108A. J Clin Exp Hematop, 61:35-41, 2021
18. Ohmachi K, Kinoshita T, Tobinai K, Ogawa G, Mizutani T, Yamauchi N, Fukuhara N, Uchida T, Yamamoto K, Miyazaki K, Tsukamoto N, Iida S, Utsumi T, Yoshida I, Imaizumi Y, Tokunaga T, Yoshida S, Masaki Y, Murayama T, Yakushijin Y, Suehiro Y, Nosaka K, Dobashi N, Kuroda J, Takamatsu Y, Maruyama D, Ando K, Ishizawa K, Ogura M, Yoshino T, Hotta T, Tsukasaki K, Nagai H. A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial. Blood Adv, 5:984-993, 2021
19. Munakata W, Shirasugi Y, Tobinai K, Onizuka M, Makita S, Suzuki R, Maruyama D, Kawai H, Izutsu K, Nakanishi T, Shiba S, Hojo S, Ando K. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma. Cancer Sci, 112:1123-1131, 2021
20. Nozaki K, Maruyama D, Maeshima AM, Tajima K, Itami J, Shichijo T, Yuda S, Suzuki T, Toyoda K, Yamauchi N, Makita S, Fukuhara S, Munakata W, Kobayashi Y, Taniguchi H, Izutsu K, Tobinai K. The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma. Eur J Haematol, 106:213-220, 2021
21. Ogura M, Kim WS, Uchida T, Uike N, Suehiro Y, Ishizawa K, Nagai H, Nagahama F, Sonehara Y, Tobinai K. Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea. Jpn J Clin Oncol, 51:218-227, 2021
22. Kinoshita T, Hatake K, Yamamoto K, Higuchi Y, Murakami S, Terui Y, Yokoyama M, Maruyama D, Makita S, Hida Y, Saito T, Tobinai K. Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study. Jpn J Clin Oncol, 51:70-77, 2021
23. Tsutsué S, Tobinai K, Yi J, Crawford B. Comparative effectiveness study of chemotherapy in follicular lymphoma patients in the rituximab era: a Japanese claims database study. Future Oncol, 17:455-469, 2021
24. Hosoba R, Makita S, Shiotsuka M, Kobayashi O, Nakano K, Muroya M, Okada N, Suzuki M, Ida H, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Maeshima AM, Matsushita H, Yamamoto N, Ohe Y, Iwata S, Izutsu K. COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma. J Clin Exp Hematop, 60:174-178, 2020
25. Matsuoka YJ, Okubo R, Shimizu Y, Tsuji K, Narisawa T, Sasaki J, Sasai H, Akashi-Tanaka S, Hamaguchi T, Iwasa T, Iwata S, Kato T, Kurotani K, Maruyama D, Mori A, Ogawa A, Sakurai N, Shimazu T, Shimizu C, Tabuchi T, Takahashi M, Takano T, Tatematsu N, Uchitomi Y, Watanabe C, Fukui T. Developing the structure of Japan's cancer survivorship guidelines using an expert panel and modified Delphi method. J Cancer Surviv, 14:273-283, 2020
26. Miyazaki K, Asano N, Yamada T, Miyawaki K, Sakai R, Igarashi T, Nishikori M, Ohata K, Sunami K, Yoshida I, Yamamoto G, Takahashi N, Okamoto M, Yano H, Nishimura Y, Tamaru S, Nishikawa M, Izutsu K, Kinoshita T, Suzumiya J, Ohshima K, Kato K, Katayama N, Yamaguchi M. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. Haematologica, 105:2308-2315, 2020
27. Kaji D, Ota Y, Sato Y, Nagafuji K, Ueda Y, Okamoto M, Terasaki Y, Tsuyama N, Matsue K, Kinoshita T, Yamamoto G, Taniguchi S, Chiba S, Ohshima K, Izutsu K. Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis. Blood Adv, 4:4442-4450, 2020
28. Matsuda S, Suzuki R, Takahashi T, Suehiro Y, Tomita N, Izutsu K, Fukuhara N, Imaizumi Y, Shimada K, Nakazato T, Yoshida I, Miyazaki K, Yamaguchi M, Suzumiya J. Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data. Int J Hematol, 112:807-816, 2020
29. Fukuhara N, Kinoshita T, Yamamoto K, Nagai H, Izutsu K, Yamamoto G, Bhargava P, Rajakumaraswamy N, Humeniuk R, Mathias A, Xing G, Fukui M, Tobinai K. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia. Jpn J Clin Oncol, 50:1395-1402, 2020
30. Ito A, Kim SW, Matsuoka KI, Kawakita T, Tanaka T, Inamoto Y, Toubai T, Fujiwara SI, Fukaya M, Kondo T, Sugita J, Nara M, Katsuoka Y, Imai Y, Nakazawa H, Kawashima I, Sakai R, Ishii A, Onizuka M, Takemura T, Terakura S, Iida H, Nakamae M, Higuchi K, Tamura S, Yoshioka S, Togitani K, Kawano N, Suzuki R, Suzumiya J, Izutsu K, Teshima T, Fukuda T. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study. Int J Hematol, 112:674-689, 2020
31. Izutsu K, Kato K, Kiyoi H, Yamamoto G, Shimada K, Akashi K. Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma. Int J Hematol, 112:504-509, 2020
32. Goto H, Makita S, Kato K, Tokushige K, Fujita T, Akashi K, Izutsu K, Teshima T. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma. Int J Clin Oncol, 25:1736-1743, 2020
33. Yoon DH, Cao J, Chen TY, Izutsu K, Kim SJ, Kwong YL, Lin TY, Thye LS, Xu B, Yang DH, Kim WS. Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. J Hematol Oncol, 13:21, 2020
34. Sunami K, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Kaneko H, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Takahashi K, Tada K, Mac? S, Guillemin-Paveau H, Iida S. Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study. Cancer Sci, 111:4526-4539, 2020
35. Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Sakai R, Fukushima N, Fukushima T, Moriuchi Y, Itoh K, Nosaka K, Choi I, Sawa M, Okamoto R, Tsujimura H, Uchida T, Suzuki S, Okamoto M, Takahashi T, Sugiura I, Onishi Y, Kohri M, Yoshida S, Kojima M, Takahashi H, Tomita A, Atsuta Y, Maruyama D, Tanaka E, Suzuki T, Kinoshita T, Ogura M, Ueda R, Mizokami M. Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma. J Hepatol, 73:285-293, 2020
36. Nakamura K, Maruyama D. What is the value of health-related quality of life in a negative superiority trial? Ann Oncol, 31:976-977, 2020
37. Ida H, Maruyama D, Maeshima AM, Kamiya T, Morio T, Izutsu K. Duodenal nodular lymphoid hyperplasia in a patient with IgA deficiency. Clin Case Rep, 8:3594-3595, 2020
38. Maeshima AM, Taniguchi H, Fujino T, Saito Y, Ito Y, Hatta S, Yuda S, Makita S, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Izutsu K. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy. Ann Hematol, 99:2141-2148, 2020
39. Maeshima AM, Taniguchi H, Ida H, Hosoba R, Fujino T, Saito Y, Yuda S, Makita S, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Izutsu K. Non-diffuse large B-cell lymphoma transformation from follicular lymphoma: a single-institution study of 19 cases. Hum Pathol, 102:33-43, 2020
40. Saito Y, Makita S, Chinen S, Kito M, Fujino T, Ida H, Hosoba R, Tanaka T, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Miyagi-Maeshima A, Matsushita H, Izutsu K. Acute megakaryoblastic leukaemia with t(1;22)(p13?3;q13?1)/RBM15-MKL1 in an adult patient following a non-mediastinal germ cell tumour. Br J Haematol, 190:e329-e332, 2020
41. Sekiguchi N, Rai S, Munakata W, Suzuki K, Handa H, Shibayama H, Endo T, Terui Y, Iwaki N, Fukuhara N, Tatetsu H, Iida S, Ishikawa T, Shiibashi R, Izutsu K. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenstr?m's macroglobulinemia. Cancer Sci, 111:3327-3337, 2020
42. Makita S, Maruyama D, Maeshima AM, Taniguchi H, Yuda S, Toyoda K, Yamauchi N, Fukuhara S, Munakata W, Kobayashi Y, Kurihara H, Izutsu K, Tobinai K. A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma. Asia Pac J Clin Oncol, 16:108-114, 2020
43. Kagami Y, Yamamoto K, Shibata T, Tobinai K, Imaizumi Y, Uchida T, Shimada K, Minauchi K, Fukuhara N, Kobayashi H, Yamauchi N, Tsujimura H, Hangaishi A, Tominaga R, Suehiro Y, Yoshida S, Inoue Y, Suzuki S, Tokuhira M, Kusumoto S, Kuroda J, Yakushijin Y, Takamatsu Y, Kubota Y, Nosaka K, Morishima S, Nakamura S, Ogura M, Maruyama D, Hotta T, Morishima Y, Tsukasaki K, Nagai H. R-CHOP-14 versus R-CHOP-14/CHASER for upfront autologous transplantation in diffuse large B-cell lymphoma: JCOG0908 study. Cancer Sci, 111:3770-3779, 2020
44. Maruyama D, Terui Y, Yamamoto K, Fukuhara N, Choi I, Kuroda J, Ando K, Hattori A, Tobinai K. Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Jpn J Clin Oncol, 50:1265-1273, 2020
45. Maloney DG, Ogura M, Fukuhara N, Davis J, Lasher J, Izquierdo M, Banerjee H, Tobinai K. A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy. Blood Adv, 4:3886-3893, 2020
46. Imaizumi Y, Iwanaga M, Nosaka K, Ishitsuka K, Ishizawa K, Ito S, Amano M, Ishida T, Uike N, Utsunomiya A, Ohshima K, Tanaka J, Tokura Y, Tobinai K, Watanabe T, Uchimaru K, Tsukasaki K. Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based study. Cancer Sci, 111:4567-4580, 2020
47. Shichijo T, Maruyama D, Yamauchi N, Maeshima AM, Sugano M, Yuda S, Tajima K, Kurihara H, Shimada K, Suzuki T, Toyoda K, Makita S, Fukuhara S, Munakata W, Suzuki T, Kobayashi Y, Taniguchi H, Minami Y, Izutsu K, Tobinai K. Transformation Scoring System (TSS): A new assessment index for clinical transformation of follicular lymphoma. Cancer Med, 9:8864-8874, 2020
48. Takezako N, Kosugi H, Matsumoto M, Iida S, Ishikawa T, Kondo Y, Ando K, Miki H, Matsumura I, Sunami K, Teshima T, Iwasaki H, Onishi Y, Kizaki M, Izutsu K, Maruyama D, Tobinai K, Ghori R, Farooqui M, Liao J, Marinello P, Matsuda K, Koh Y, Shimamoto T, Suzuki K. Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients. Int J Hematol, 112:640-649, 2020
49. Makita S, Hosoba R, Tobinai K. Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma. Expert Opin Drug Saf, 19:1105-1120, 2020
50. Tsutsué S, Tobinai K, Yi J, Crawford B. Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma. PLoS One, 15:e0237509, 2020
51. Zhu J, Yeoh EM, Maeda Y, Tobinai K. Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis. Leuk Lymphoma, 61:2145-2152, 2020
52. Makita S, Maruyama D, Tobinai K. Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma. Onco Targets Ther, 13:5993-6009, 2020